TMPRSS5 Inhibitors

Chemical inhibitors of TMPRSS5 include a variety of compounds that interfere with the protein's function by binding to its active site or a domain critical for its proteolytic activity. Camostat and Nafamostat are serine protease inhibitors that directly target the active site of TMPRSS5, preventing the cleavage of substrates that the enzyme would typically process. This direct inhibition is achieved through the binding of these inhibitors to the active site of TMPRSS5, forming a complex that renders the protease inactive. AEBSF operates similarly by irreversibly reacting with the serine residue within the active site of TMPRSS5, leading to sustained inhibition. Aprotinin takes a slightly different approach by forming a reversible stoichiometric complex with TMPRSS5, which impedes substrate access and, therefore, inhibits the protein's function. Leupeptin, while traditionally known as a cysteine protease inhibitor, also exerts its effects on TMPRSS5 by binding reversibly to the active site, thus preventing enzymatic activity.

In addition to these direct inhibitors, there are chemical compounds that can inhibit TMPRSS5 by mechanisms that involve binding to domains with structural or functional similarity to other protease families. Bromhexine, although primarily known for its effects on TMPRSS2, is postulated to inhibit TMPRSS5 through a similar mechanism that involves interference with the protease's active site or substrate binding. E-64, a cysteine protease inhibitor, may inhibit TMPRSS5 if it possesses a similar active site configuration, by covalently binding to the thiol group of cysteine residues. Gabexate targets TMPRSS5 by blocking its serine protease domain, thus obstructing its enzymatic function. Sivelestat, although selective for neutrophil elastase, can inhibit TMPRSS5 by occupying the serine residue in the active site. Marimastat and Ilomastat, known as matrix metalloproteinase inhibitors, may inhibit TMPRSS5 if the protein interacts with or resembles matrix metalloproteinases in structure or function. Pepstatin A, an aspartyl protease inhibitor, might inhibit TMPRSS5 if the protease has an aspartyl protease-like domain or activity, by attaching to its active site.